Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Podcast

Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics Evaluation and Research; Bayer cuts 2,000 more employees; Eli Lilly’s Zepbound scores again; and the Galapagos story turns again.

May 14, 2025

2 min read

Heather McKenzie

Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.

Obesity

Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.

May 12, 2025

2 min read

Tristan Manalac

Radiopharmaceuticals

Radiopharma Powerhouses Push Frontiers With New Indications, Innovation

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a radiopharmaceuticals market that could top $16 billion by 2033.

May 12, 2025

9 min read

Tristan Manalac

Job Trends

2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.

May 8, 2025

3 min read

Angela Gabriel

Hiring collage showing HR checking applicant information

Job Trends

Hiring Outlook: Biopharma Job Market Yet To Surge, but Layoffs Decline

Although the job market did not pick up in April, layoffs were down year over year and month over month, according to BioSpace tallies. Meanwhile, Amgen, Novartis, Regeneron and Roche announced U.S. manufacturing investments that are sparking job creation.

May 7, 2025

3 min read

Angela Gabriel

Podcast

Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will require placebo-controlled trials for all vaccine approvals; tariff threats hit BioNTech; Novo Nordisk’s FDA application for an oral version of Wegovy is accepted; and more.

May 7, 2025

1 min read

Heather McKenzie

Brain shaped maze. Conceptual image of science and medicine. 3D illustration.

ALS

Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal

The Alchemab deal will further strengthen Lilly’s early-stage pipeline for amyotrophic lateral sclerosis, coming less than a year after the pharma licensed QurAlis’ antisense oligonucleotide to correct a specific protein alteration in ALS.

May 6, 2025

2 min read

Tristan Manalac

Flat 3d isometric businessman hands show thumb up finger gesture to business winner. Business success concept.

Earnings

Lilly Unfazed as CVS Picks Novo’s Side in Obesity Market Battle

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

May 1, 2025

3 min read

Annalee Armstrong

Contemporary art collage. Hand put money to golden stack of coins, meaning income from investment. Concept of business strategy, investment, development, market, finance.

Earnings

Lilly’s Revenue Leaps 45% Thanks to Zepbound, Mounjaro, Of Course

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 billion for the quarter while Zepbound in weight loss booked $2.31 billion.

May 1, 2025

1 min read

Annalee Armstrong

JOBS